Literature DB >> 2536329

Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions.

K Akahane1, A Tojo, H Fukamachi, T Kitamura, T Saito, A Urabe, F Takaku.   

Abstract

Specific binding sites for erythropoietin (Epo) were shown in normal and anemic rat bone marrow cells using [125I]labeled human recombinant Epo. When rats were treated once or several times with phenylhydrazine or malotilate, or by phlebotomy, the serum Epo level determined by RIA began to increase rapidly. Thereafter, both the number of erythroid colony-forming unit (CFU-E)-derived colonies and the Epo binding capacity of bone marrow cells increased almost simultaneously in response to induced anemic states, suggesting that the amount of Epo binding in bone marrow cells may reflect in vivo erythropoiesis. Scatchard analysis of the binding data from normal rats revealed the presence of a single class of binding sites (Kd = 0.18 +/- 0.04 nM, 38 +/- 5 sites/cell). In anemic states, the apparent average receptor number per cell increased (52-62 sites/cell) without changing in binding affinity toward Epo. Furthermore, [125I]Epo was cross-linked to the cell surface molecule of approximately 165 kd in nonreducing conditions and 75 kd in reducing conditions. Autoradiographic analysis indicated that Epo receptors were distributed on immature erythroid cells. Proerythroblasts were the most heavily labeled, whereas orthochromatic erythroblasts and cells of myeloid and lymphoid lineages were not labeled. Calculations based on Scatchard and autoradiographic analysis showed that proerythroblasts have 390 receptor sites per cell, twice as many as basophilic or polychromatophilic erythroblasts have. These results are consistent with the stage-specific action of Epo in physiological differentiation of erythroid cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536329

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors:  Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

3.  Sensitivity of CFU-E to exogenous erythropoietin in benzene-treated mice.

Authors:  E Necas; E Barthel; H J Seidel
Journal:  Ann Hematol       Date:  1992-01       Impact factor: 3.673

Review 4.  Erythropoietin receptor. Subunit structure and activation.

Authors:  A D D'Andrea; L I Zon
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.

Authors:  U Gladziwa; U Klotz; K Bäumer; R Zollinger; H Mann; H G Sieberth
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

6.  Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Authors:  Pardeep Heir; Tharan Srikumar; George Bikopoulos; Severa Bunda; Betty P Poon; Jeffrey E Lee; Brian Raught; Michael Ohh
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

7.  A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats.

Authors:  Ly Minh Nguyen; Zhichuan Li; Xiaoyu Yan; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-07       Impact factor: 2.745

8.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.